Introduction This is the third article in LuTra Studio’s ADC series, written for readers without a chemistry or ADC engineering background  who want to understand why many antibody–drug conjugate programs fail despite having strong targets and potent payloads . This article focuses on ADC linker design and conjugation strategy —two elements often treated as technical details, but which frequently become structural failure points  in clinical development and manufacturing scal